Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact
Boston Scientific (BSX) fell 5.81% to $42.44 after cutting Q4 and full-year guidance due to a cyberattack. The company reported 1.5% sales growth and $0.73 adjusted EPS for Q3, missing estimates. Management expects a slow recovery, with 3.75% sales growth projected for 2026. Trading volume was 66.8M shares, 234% above average. The S&P 500 and Nasdaq Composite both rose slightly.
How this was made
The 30-second read
Why it matters
The guidance cut is likely to keep the stock under pressure until tangible progress on the cyber recovery and acquisition integration is shown.
Market read
New guidance cut for a mid‑cap medical‑device firm, immediate price impact and sector‑wide risk considerations.
What to watch
Potential upside from the pending Penumbra acquisition and long‑term growth investments.
Background
Boston Scientific disclosed that an eight‑day cyberattack reduced sales growth by 300 bps and EPS by $0.07, prompting a lower guidance.
Ticker impact
Boston Scientific cut Q4 and full-year EPS guidance after a cyberattack, causing a 6% share drop.
downward pressure as investors price in lower sales and EPS forecasts
The guidance reduction is a fresh, material fact and the stock already fell 6% on the news.
Market effects
Medical‑device peers may face heightened scrutiny of cyber risk and guidance outlook.
U.S. equity markets could see modest drag in the healthcare sector.
Limited to U.S. listed medical‑device companies.
Counterpoint
If the Penumbra integration succeeds, BSX could rebound despite short‑term guidance weakness.
Key entities
- companyBoston Scientific
Medical‑device maker reporting guidance cut.
